Seer, Inc. (SEER)
- Previous Close
2.2900 - Open
2.3000 - Bid 2.3800 x 100
- Ask 2.3900 x 100
- Day's Range
2.3000 - 2.4290 - 52 Week Range
1.5100 - 2.5000 - Volume
83,339 - Avg. Volume
296,745 - Market Cap (intraday)
140.529M - Beta (5Y Monthly) 1.46
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3000 - Earnings Date Nov 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
seer.bioRecent News: SEER
View MorePerformance Overview: SEER
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SEER
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SEER
View MoreValuation Measures
Market Cap
135.03M
Enterprise Value
-86.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.28
Price/Book (mrq)
0.39
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.92%
Return on Equity (ttm)
-22.03%
Revenue (ttm)
14.61M
Net Income Avi to Common (ttm)
-82.66M
Diluted EPS (ttm)
-1.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
247.6M
Total Debt/Equity (mrq)
7.69%
Levered Free Cash Flow (ttm)
-31.91M